Elsevier

The Lancet

Volume 369, Issue 9558, 27 January–2 February 2007, Pages 249-250
The Lancet

Comment
Intravenous alteplase for ischaemic stroke

https://doi.org/10.1016/S0140-6736(07)60120-2Get rights and content

References (14)

  • N Wahlgren et al.

    Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study

    Lancet

    (2007)
  • Tissue plasminogen activator for acute ischemic stroke

    N Engl J Med

    (1995)
  • GW Albers et al.

    Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study

    JAMA

    (2000)
  • MD Hill et al.

    Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study

    CMAJ

    (2005)
  • W Hacke et al.

    Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials

    Lancet

    (2004)
  • M Fiorelli et al.

    Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort

    Stroke

    (1999)
  • D Tanne et al.

    Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey

    Neurology

    (1999)
There are more references available in the full text version of this article.

Cited by (58)

  • Thrombectomy for Stroke Caused by Cardiac Myxoma

    2020, Journal of Stroke and Cerebrovascular Diseases
  • Acute Ischemic Stroke Intervention

    2016, Journal of the American College of Cardiology
    Citation Excerpt :

    Although the FDA did not modify the original indication for use of IV-rtPA beyond 3 h, recent stroke guidelines from the American Heart Association (AHA) recommended using it up to 4.5 h from onset of symptoms in eligible patients (2). Despite this recommendation, the use of IV-rtPA is estimated to occur in <3% of patients presenting with AIS (9). The narrow therapeutic time window of 4.5 h is the most common reason that patients do not receive IV-rtPA, along with a few others (Table 1).

  • Endovascular reperfusion strategies for acute stroke

    2016, JACC: Cardiovascular Interventions
View all citing articles on Scopus
View full text